Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ALB | P02768 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.42 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21417219 | 0.91 | ALDH1A1 (0.71) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL20327576 | 0.91 | ALDH1A1 (0.71) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL21132949 | 0.87 | ALDH1A1 (0.69) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL21417395 | 0.87 | ALDH1A1 (0.69) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL25057498 | 0.87 | ALDH1A1 (0.69) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| Didanosine SCHEMBL7787270 | 0.86 | ALDH1A1 (0.84) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| Dideoxy Guanosine Triphosphate SCHEMBL24370775 | 0.86 | POLB (0.60) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| Dideoxy Guanosine Triphosphate SCHEMBL80109 | 0.86 | POLB (0.60) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL18095578 | 0.86 | POLB (0.60) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| Dideoxy Guanosine Triphosphate SCHEMBL25720613 | 0.86 | POLB (0.60) | ALDH1A1LMNAALBMAPK1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146263-A1 | GENE EDITING SYSTEMS COMPRISING REVERSE TRANSCRIPTASES | METAGENOMI, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4743569-A1 | METHODS OF AMPLIFYING TEMPLATE NUCLEIC ACID USING A THERMOSTABLE TTHPRIMPOL | 4basebio, S.L.U. (ES) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132392-A1 | GENE EDITING SYSTEMS COMPRISING REVERSE TRANSCRIPTASES | Metagenomi Therapeutics, Inc. | 2026-05-14 | — | — | US | disclosed |
| US-20260115321-A1 | SUPPLEMENTATION OF LIVER ENZYME EXPRESSION | Metagenomi Therapeutics, Inc. | 2026-04-30 | — | — | US | disclosed |
| US-20260115319-A1 | SUPPLEMENTATION OF LIVER ENZYME EXPRESSION | Metagenomi Therapeutics, Inc. | 2026-04-30 | — | — | US | disclosed |
| US-20260115320-A1 | SUPPLEMENTATION OF LIVER ENZYME EXPRESSION | Metagenomi Therapeutics, Inc. | 2026-04-30 | — | — | US | disclosed |
| US-20260109752-A1 | PLATFORMS, COMPOSITIONS, AND METHODS FOR THERAPEUTIC DELIVERY | TELOS THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599678-B2 | Methods and compositions for genomic integration | CREATE MEDICINES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4716752-A2 | ENDONUCLEASE SYSTEMS | Metagenomi, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12590959-B2 | Systems and methods for measuring cell signaling protein activity | OCTANT, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2022063160-A1 | COMPOSITIONS AND METHODS FOR GENETIC MODIFICATION AND TARGETING | QIHAN-EGENESIS HONG KONG LIMITED (CN) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022066335-A1 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | METAGENOMI IP TECHNOLOGIES, LLC (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20220090141-A1 | TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME | MOLECULAR TRANSFER, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2022057939-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CD47 ANTIBODY AND PD-1/PD-L1 INHIBITOR | I-MAB BIOPHARMA CO., LTD. (CN) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056324-A1 | BASE EDITING ENZYMES | METAGENOMI IP TECHNOLOGIES, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056301-A1 | BASE EDITING ENZYMES | METAGENOMI IP TECHNOLOGIES, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3418394-B1 | ASSAY METHOD FOR GENETIC ANALYSIS | ROCHE DIAGNOSTICS GMBH (DE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022046662-A1 | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCES | METAGENOMI IP TECHNOLOGIES, LLC (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022031783-A2 | ADAPTER POLYPEPTIDES AND METHODS OF USING THE SAME | OHIO STATE INNOVATION FOUNDATION (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146263-A1 | GENE EDITING SYSTEMS COMPRISING REVERSE TRANSCRIPTASES | RNGTT, RTCB, ADA | ALDH1A1 2960/4885LMNA 1494/4885ALB 1367/4885 |
| US-20260132392-A1 | GENE EDITING SYSTEMS COMPRISING REVERSE TRANSCRIPTASES | UPF1, RNGTT, JMJD7 | ALDH1A1 3092/4885LMNA 1065/4885ALB 3824/4885 |
| US-12590959-B2 | Systems and methods for measuring cell signaling protein activity | ADCY6, ADCY2, ADCY3 | ALDH1A1 2279/4885LMNA 2579/4885ALB 4848/4885 |
| US-12599678-B2 | Methods and compositions for genomic integration | RNGTT, UPF1, LNPEP | ALDH1A1 3589/4885LMNA 62/4885ALB 2542/4885 |
| US-20260115319-A1 | SUPPLEMENTATION OF LIVER ENZYME EXPRESSION | F8, F13B, F2 | ALDH1A1 1828/4885LMNA 1911/4885ALB 30/4885 |
| US-20260109752-A1 | PLATFORMS, COMPOSITIONS, AND METHODS FOR THERAPEUTIC DELIVERY | NECTIN4, CD47, CD274 | ALDH1A1 3174/4885LMNA 3094/4885ALB 1479/4885 |
| US-20260115321-A1 | SUPPLEMENTATION OF LIVER ENZYME EXPRESSION | F8, F13B, F2 | ALDH1A1 1825/4885LMNA 1773/4885ALB 30/4885 |
| US-20260115320-A1 | SUPPLEMENTATION OF LIVER ENZYME EXPRESSION | F8, F13B, F2 | ALDH1A1 1809/4885LMNA 1762/4885ALB 30/4885 |
| US-20220090141-A1 | TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME | TIAL1, NPC1L1, LIPA | ALDH1A1 3840/4885LMNA 2520/4885ALB 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.